1. Evaluation of the roma test for ovarian cancer diagnosis
Main Article Content
Abstract
The CA125 and HE4 tests are the most commonly used in the diagnosis of ovarian cancer, with each playing a unique role in the diagnosis and treatment monitoring. ROMA test (Risk of Ovarian Malignancy Algorithm) is an algorithm-based test that combines the results of CA125 and HE4, along with menstrual status, to assess the possibility of ovarian cancer. In this study, we evaluated the effectiveness of the ROMA test in detecting ovarian cancer in women visiting Hanoi Medical University Hospital with ovarian tumors. We evaluate the ROMA value for the ability to detect ovarian cancer based on ultrasound results and pathology results. Data collected from 77 patients showed that the ROMA test results were able to classify patients as high-risk up to 83.3%, while the CA125 test alone was 66.6% or the HE4 test was 45.84%. Thus, the ROMA test has the ability to detect a higher risk of ovarian cancer than previous single-marker tests. This is a recommendation for doctors when they are ordering tests to diagnose ovarian cancer.
Article Details
Keywords
Ovarian cancer, ROMA-test, HE4, CA125
References
2. Assessment UENC for E. SEER cancer statistics review, 1975-2012. Published March 15, 2009. Accessed November 25, 2022. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3420543.
3. Chien J, Poole EM. Ovarian cancer prevention, screening and early detection: Report from the 11th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2017; 27(9): S20-S22. doi: 10.1097/IGC.0000000000001118.
4. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020; 12(12): 3730. doi: 10.3390/cancers12123730.
5. Ron IG, Inbar M, Gelernter I, et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand. 1994; 73(8): 658-662. doi: 10.3109/00016349409013462.
6. Ahmed AA, Abdou AM. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. Curr Probl Cancer. 2019; 43(5): 450-460. doi: 10.1016/j.currproblcancer.2018.12.004.
7. Yang WL, Lu Z, Bast RC. The Role of Biomarkers in the Management of Epithelial Ovarian Cancer. Expert Rev Mol Diagn. 2017; 17(6): 577-591. doi: 10.1080/14737159.2017.1326820.
8. WEI S, LI H, ZHANG B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016; 5(1): 41-44. doi: 10.3892/br.2016.682.
9. Fujiwara H, Suzuki M, Takeshima N, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015; 36(2): 1045-1053. doi: 10.1007/s13277-014-2738-7.
10. Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22(4): 244-252. doi: 10.3802/jgo.2011.22.4.244.
11. Cho HY, Park SH, Park YH, et al. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. J Korean Med Sci. 2015;30(12):1777-1783. doi: 10.3346/jkms.2015.30.12.1777.
12. Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med. 2011; 49(3): 527-534. doi: 10.1515/CCLM.2011.085.
13. Lowe KA, Shah C, Wallace E, et al. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(9): 2480-2487. doi: 10.1158/1055-9965.EPI-08-0150.
14. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum Levels of the Ovarian Cancer Biomarker HE4 are decreased in Pregnancy and Increase with Age. Am J Obstet Gynecol. 2012; 206(4): 349.e1-349.e7. doi: 10.1016/j.ajog.2011.12.028.
15. Barr CE, Funston G, Jeevan D, Sundar S, Mounce LTA, Crosbie EJ. The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. Cancers. 2022;14(9):2124. doi: 10.3390/cancers14092124.